Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 |
| clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma(PIOPPO) | terminated | Phase 2 | 30 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | terminated | Early Phase 1 | 2 | Floor Backes, MDOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | terminated | Phase 2 | 16 | Georgetown UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | terminated | Phase 1 | 13 | Biomea Fusion Inc.INDUSTRY | 2 | Feb 7, 2025 | clinicaltrials |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | terminated | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | terminated | Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma | terminated | N/A | 8 | Shantou University Medical CollegeOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | terminated | Phase 2 | 5 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | terminated | N/A | 87 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 18 | Janssen Research & Development, LLCINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | terminated | Phase 1 | 19 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | terminated | Phase 2 | 8 | Kimberly Perez, MDOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | terminated | Phase 1 | 11 | Radionetics OncologyINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05119010 | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma(KETOREIN) | terminated | N/A | 3 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade(Decrescendo) | terminated | Phase 2 | 139 | Jules Bordet InstituteOTHER | 6 | Dec 4, 2024 | clinicaltrials |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | terminated | Phase 2 | 3 | ImaginAb, Inc.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC(TATE) | terminated | Phase 2 | 6 | Teclison Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | terminated | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | NantBioScience, Inc.INDUSTRY | 13 | Nov 8, 2024 | clinicaltrials |
| NCT03366012 | Rapid Assessment of Esophageal Adenocarcinoma Risk Test(REACT) | terminated | N/A | 51 | Columbia UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 66 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | terminated | Phase 4 | 12 | Indiana UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 54 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy | terminated | Phase 2 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients | terminated | Phase 1 | 1 | SLK Kliniken Heilbronn GmbHOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2025source: clinicaltrials